gabexate has been researched along with Acantholysis Bullosa in 2 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kaneko, F | 1 |
Tsukinaga, I | 1 |
Ando, M | 1 |
Ohkawara, A | 1 |
Oguchi, H | 1 |
Oikawa, K | 1 |
Nagai, M | 1 |
Ikeda, S | 1 |
Manabe, M | 1 |
Muramatsu, T | 1 |
Takamori, K | 1 |
Ogawa, H | 1 |
2 other studies available for gabexate and Acantholysis Bullosa
Article | Year |
---|---|
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
Topics: Adolescent; Child; Epidermolysis Bullosa; Esters; Female; Gabexate; Genes, Recessive; Guanidines; HL | 1989 |
Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate.
Topics: Administration, Topical; Adolescent; Adult; Blister; Child; Epidermolysis Bullosa; Esters; Female; G | 1988 |